IL-1β in atherosclerotic vascular calcification: From bench to bedside

Area of Science:

• Cardiovascular Medicine
• Immunology
• Pathophysiology

Background:

• Atherosclerotic vascular calcification is a major risk factor for mortality in cardiovascular diseases.
• Inflammation assessment is critical for managing cardiovascular conditions.
• Interleukin-1 beta (IL-1β) is a key proinflammatory cytokine implicated in atherosclerotic vascular calcification.

Purpose of the Study:

• To review the role of IL-1β in atherosclerotic vascular calcification.
• To summarize clinical trial data on anti-IL-1β therapies for cardiovascular diseases.
• To elucidate the mechanisms by which IL-1β influences cardiovascular events.

Main Methods:

• Literature review of current knowledge on IL-1β in vascular calcification.
• Analysis of findings from large-scale population cohort trials.
• Examination of recent clinical trial results for anti-IL-1β therapies.

Main Results:

• IL-1β plays a significant role in the pathogenesis of atherosclerotic vascular calcification.
• Anti-IL-1β therapy has demonstrated a clinical reduction in cardiovascular events in population studies.
• The exact mechanism by which anti-IL-1β therapy impacts cardiovascular events via vascular calcification is not fully understood.

Conclusions:

• IL-1β is a critical mediator in atherosclerotic vascular calcification.
• Anti-IL-1β therapies represent a potential treatment strategy for cardiovascular diseases.
• Further research is needed to clarify the mechanisms underlying the cardioprotective effects of anti-IL-1β therapy.